Articles related to ANTIBIOTICS
Amoxicillin Shortage Continues, Alternatives Available
The shortage is driven by increased prescribing due to bacterial infection coexisting with RSV infection, and in cases where it is not possible to tell if the patient is experiencing a bacterial or viral URI. Substitute antibiotics to consider include cephalosporins and amoxicillin-clavulanate.
Clinical Pharmacology November 29th 2022
Is De-Escalation an Effective Stewardship Strategy?
Although many organizations advise reducing the range of antibiotic therapy for hospitalized patients in light of laboratory findings, some are challenging the validity of the practice. One expert argued that there are insufficiently strong data on spectrum de-escalation to determine whether it improves outcomes.
Clinical Pharmacology September 8th 2022
A Clinical Trial and Another Clinical Practice Bites the Dust, or Should There Not Be an Appendix?
A commentary with perspective on the clinical practice implications of the Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) trial, which demonstrated short-term noninferiority of antibiotic therapy vs. surgical therapy for patients diagnosed with acute appendicitis.
Emergency Medicine June 13th 2022
Dramatic Changes in the Recommended Approach to Diverticulitis
New guidelines recommend that internists treat uncomplicated diverticulitis in an outpatient setting without the use of antibiotics. The new guidelines on diagnosis and management of patients with diverticulitis have been published by the Annals of Internal Medicine. And they are stirring up debate among physicians.
Emergency Medicine April 12th 2022
Putting ACP’s Guidance on Shorter Courses for Antibiotics to Practice
In practice, “standard” duration of antibiotic therapy is often based on archaic studies. Newer evidence shows that shorter durations are often a better choice and that antibiotic resistance is more likely to develop with longer durations of therapy. Here are the recommendations applied to four commonly treated infections.
Allergy & Immunology October 12th 2021
Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch
In a study in the journal Nature Cancer, the researchers found that in laboratory cell lines and tumor models novobiocin selectively killed tumor cells with abnormal BRCA1 or BRCA2 genes, which help repair damaged DNA. The drug, developed in the 1950s and largely supplanted by newer drugs, was effective even in tumors resistant to agents known as PARP inhibitors, which have become a prime therapy for cancers with DNA-repair glitches.
Family Medicine/General Practice July 26th 2021